The type 2 diabetes drug Invokamet now has a once-a-day version.
The Food and Drug Administration has given its okay to Invokamet XR. It’s a combination of the traditional Invokana (canagliflozin) with an extended-release version of metformin. Metformin is frequently prescribed as an initial therapy for type 2 diabetes. Invokana is the most prescribed sodium glucose inhibitor. The extended release component allows the drug to be taken once a day.
Good results reported from research
Drug maker Janssen Pharmaceuticals reports its studies show the combination of Invokana and metformin reduces A1C significantly more than metformin alone. A1C is a measure of average blood glucose over the past two to three months. Treatment with Invokana as an add-on to metformin also demonstrated greater reductions in body weight and systolic blood pressure.
Invokamet XR comes in four dosages: tablets containing canagliflozin 50 mg or 150 mg, and metformin XR 500 mg or 1000 mg. The recommended dosing is two tablets each day taken with the morning meal. The FDA is requiring a warning on the box about lactic acidosis. That is a rare but serious complication that can occur due to accumulation of too much metformin.
Of the approximately 29 million people who have diabetes in the United States, 90 to 95 percent of them have type 2 diabetes. According to the American Diabetic Association, in type 2 diabetes the body fails to use insulin properly. This is called insulin resistance. At first, the pancreas makes extra insulin to make up for it. But, over time the pancreas isn’t able to keep up and can’t make enough insulin to keep your blood glucose levels normal. Type 2 is treated with lifestyle changes pills and insulin. About 1.4 million people are diagnosed with diabetes each year. More than 86 million others have symptoms indicating they are close to becoming diabetic.